| ||||||||||||||||
| ||||||||||||||||
— Wyeth —Top tagsYou have executed a tag search on The Deal Newsweekly. To the right you will find a comprehensive list of stories tagged "Wyeth." Below are the most-popular tags for The Deal Newsweekly. On the right of the page you will find a search box to dig deeper into our content.
Community
 Entries tagged "Wyeth"Risk, reconsideredThe architecture of recent M&A deals reflects a changed environment. On the whole there has been an increased focus on risk allocation. Scenes from the slowdownM&A activity may have stalled during the first half of the year, but deal lawyers still had plenty to talk about. Something old, new, borrowed and blueHave strategics adopted conditionality from the private equity arena? License and registration, pleaseEven for a company the size of Amgen, investors are scrutinizing new drug partnership terms. Deep cleansing treatmentAs Pfizer prepares for another digestive challenge in the form of Wyeth, it is trying to unload some compounds it already has. That's a spicy meatballSkepticism abounds over Pfizer's ability to digest Wyeth. Movers & shakers: March 30, 2009Nomura Holdings Inc. hired Andrea Pellegrini as co-chairman for Italy and head of investment banking, partnering with Alessandro Cremona, chairman of investment banking for Italy.... A whole new ballgameRecent big-ticket pharma deals illustrate the evolution of financing outs and breakup fees. Paging Dr. SchollThe consumer-products subplot in the pharmaceutical megamergers. Little pharma bluesAs the economy foundered, drug industry insiders looked forward to an M&A frenzy. But with a few exceptions, deals occurred only at the top of the food chain. Merck, Schering play follow the pharmaDamian Ridealgh and other Fried Frank attorneys advised Merck on its deal for Schering. The big trialFrom VC to licensing, Exelixis has done every kind of deal to keep itself afloat, except one. Is an acquisition next? Exit papersWhen Mars signed a deal to buy Wrigley, it reserved the right to skip out. That has since become the industry standard. Dead, temporarilyThe media's decided that Wall Street is definitely kaput. Trying to figure what's there instead is more of a problem. Critical, if improvingSome financing markets are open, others are closed. The future remains desperately uncertain, but at least the patient shows signs of life. Surprise!For sheer drama, Roche's hostile, discounted bid for Genentech tops even Pfizer's bid for Wyeth. Pfizer taps Cadwalader for Wyeth adviceMost noteworthy in the $68B deal may be the size of the reverse termination fee: $4.5B. Mood enhancersDrug companies get a warm reception in the debt market these days. Risk Arbitrage: Feb. 9, 20092009 has begun better than it might have on the M&A front. Transactions: Feb. 9, 2009In the boom, a bewildering number of markets seemed to merge to one Metamarket. Now that it's all fractured, putting it back together is quite a chore. This won't hurt a bitAn examination of U.S. healthcare under the Obama administration. The Supreme questionDoes the FDA trump the states? Beyond fluxMarket chaos has effectively stifled most M&A activities. But investment bankers already look ahead to when a kind of dealmaking normalcy prevails. Litigation riskFASB weighs requiring companies to estimate their exposure to legal damages; business tries to bury the idea. | ||||||||||||||||
|
|
|
|
|
